Novel structurally related compounds reactivate latent HIV-1 in a bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation.
about
HIV-1 eradication strategies: design and assessmentRecent developments in human immunodeficiency virus-1 latency researchHistone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing.Prospects for treatment of latent HIV.Rapid quantification of the latent reservoir for HIV-1 using a viral outgrowth assayMeasuring turnover of SIV DNA in resting CD4+ T cells using pyrosequencing: implications for the timing of HIV eradication therapiesA primary CD4(+) T cell model of HIV-1 latency established after activation through the T cell receptor and subsequent return to quiescenceA hardwired HIV latency program.Elimination of HIV-1-Infected Primary T Cell Reservoirs in an In Vitro Model of Latency.Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations.HIV Integration Site Analysis of Cellular Models of HIV Latency with a Probe-Enriched Next-Generation Sequencing Assay.Targeting HIV latency: pharmacologic strategies toward eradication.Substituted oxines inhibit endothelial cell proliferation and angiogenesis.Combined approaches for HIV cure.Developing strategies for HIV-1 eradicationAttacking the HIV reservoir from the immune and viral perspective.Is specific HIV eradication from the brain possible or needed?HIV-1 latency: an update of molecular mechanisms and therapeutic strategies.Progress and challenges in the use of latent HIV-1 reactivating agentsBET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism.HIV cure: knocking on the door.
P2860
Q26864933-6F9FD055-84ED-46DD-B7D7-3A1CCAC0F73FQ27013114-59FCD4D2-9D7A-4CBE-BE9E-7150F54E3440Q28537694-EE974C21-69EE-43D2-81E9-C19B31A7CC8DQ30424413-99056A7E-870A-4947-BA11-B11C2721B4B4Q34758220-BEDC8B2F-FD4D-4F60-879E-E6DFAA13BE7BQ35141776-122F2E42-3DEE-4808-B3BA-CF63F567C856Q35229849-04307294-E5AC-4F62-90F2-912DC8469EE8Q35400385-10DC3A45-FE0B-4204-9C81-87A81A8DF8E9Q35637027-758D001C-DDF1-4D42-A5E3-0E227BDFC916Q35720063-3052E1CE-7F25-460B-956D-C1C6BEA62D30Q35935136-B6C67902-C850-4534-AFBB-CE2ECF83C137Q36901950-B2CAD806-F5D9-4A79-BAF9-266A5115CCFEQ37156368-CFE6C1C3-6C01-474E-B6EF-3F8826EA0E67Q37664312-65E7931A-3D86-48A9-AB07-EFA0CFCFC3D0Q38032363-192AD025-EA1E-4079-96AA-0B5A099C4633Q38067646-1E41F84C-0A90-4BB7-8FCF-83FB16C63F52Q38071699-4C5A8BD5-48E3-47A5-A31B-E7A8360D63FCQ38204866-72A364B0-4098-4A72-B9DC-BADF65A3957BQ38509230-19096DD2-FBC9-42CF-A45C-8F43C48C1CAAQ41641646-9ABB25F8-150E-4289-AFE7-6F7C218BEDEDQ42266102-C8207BF9-C3BA-4418-83FF-CD1C027AA809
P2860
Novel structurally related compounds reactivate latent HIV-1 in a bcl-2-transduced primary CD4+ T cell model without inducing global T cell activation.
description
2011 nî lūn-bûn
@nan
2011 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Novel structurally related com ...... cing global T cell activation.
@ast
Novel structurally related com ...... cing global T cell activation.
@en
Novel structurally related com ...... cing global T cell activation.
@nl
type
label
Novel structurally related com ...... cing global T cell activation.
@ast
Novel structurally related com ...... cing global T cell activation.
@en
Novel structurally related com ...... cing global T cell activation.
@nl
prefLabel
Novel structurally related com ...... cing global T cell activation.
@ast
Novel structurally related com ...... cing global T cell activation.
@en
Novel structurally related com ...... cing global T cell activation.
@nl
P2093
P2860
P356
P1476
Novel structurally related com ...... cing global T cell activation.
@en
P2093
Joseph A Lopez
Neeta S Shroff
Shridhar Bhat
Sifei Xing
P2860
P304
P356
10.1093/JAC/DKR496
P407
P577
2011-12-07T00:00:00Z